NEOK Bio vs Beam Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Beam Therapeutics leads in AI visibility (38 vs 27)
NEOK Bio logo

NEOK Bio

EmergingBioTech

Neuroscience

NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.

AI VisibilityBeta
Overall Score
D27
Category Rank
#2 of 2
AI Consensus
56%
Trend
up
Per Platform
ChatGPT
34
Perplexity
18
Gemini
36

About

NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.

Full profile
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile

AI Visibility Head-to-Head

27
Overall Score
38
#2
Category Rank
#1
56
AI Consensus
64
up
Trend
up
34
ChatGPT
44
18
Perplexity
34
36
Gemini
29
28
Claude
30
33
Grok
34

Key Details

Category
Neuroscience
Base Editing Gene Therapy
Tier
Emerging
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only NEOK Bio
Neuroscience
Only Beam Therapeutics
Base Editing Gene Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.